The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

LJN452 is Novartis’ most advanced of two Farnesoid X receptor (FXR) agonists. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Hughes states that ...

Gerdau S/A Ord-0.31% R$41.41B ...

Vice President Kamala Harris’ first video to her supporters after the election stunned social media users Tuesday. The video, shared by the Democratic Party’s official X account, featured ...

Iga Swiatek has been suspended for one month due to a doping violation, the International Tennis Integrity Agency announced today. Swiatek initially tested posted for the banned substance ...